Serum Clusterin Level as a Biomarker for Hepatitis C Virus Related Hepatocellular Carcinoma
/ 0
- Details
- Category: Vol. 85, June 2017
- Hits: 567
Serum Clusterin Level as a Biomarker for Hepatitis C Virus Related Hepatocellular Carcinoma, ADEL A. MOSTAFA, HALA M. EL-FEKY, EHAB M. REYAD and ZAINAB A. HAMMAM
Abstract
Background: Hepatocellular Carcinoma (HCC) is a com-mon human cancer and is an increasing problem in Egypt. Clusterin (CLU) is a 449 amino acid, heterodimeric glycopro-tein with a plausible role in the regeneration, migration, and anti-apoptosis of tumor cells.
Objective: The aim of this study was to evaluate the role of serum CLU level as a biomarker for diagnosis of hepatitis C virus-related HCC and comparing its level with focal lesions characters.
Subjects and Methods: Twenty cases of apparently healthy subjects matched in age and sex with the patients groups: 27 cases of hepatitis C virus-related liver cirrhosis, and 35 HCC cases (post HCV infection) were included in this study. Serum CLU concentration was determined using a quantitative sandwich enzyme immunoassay technique.
Results: Serum clusterin level showed a significant in-crease in the HCC group compared to the control group (122. 14-}63.02ng/ml vs. 101.50-}10.37ng/ml) and to the cir-rhotic group (122. 14-}63.02ng/ml vs. 67.38-}54.73ng/ml), while a significant decrease in serum clusterin level was found in the cirrhotc group compared to the control group (67.38-} 54.73ng/ml vs. 101.50-}10.37ng/ml). Serum clusterin level was significantly increased according to the progression of Barcelona Clinic Liver Cancer staging system and also its level was increased by increasing the size of focal lesion. Receiver operator characteristic curve showed that at cutoff value 115ng/ml, serum clusterin yielded 91.18% sensitivity, 89.58% specificity, 86.1% PPV% and 93.5% NPV for HCC diagnosis.
Conclusion: Serum clusterin might be used as a useful biomarker in screening of high risk populations and for diagnosis of HCC.